1,713 reports of this reaction
6.8% of all BIMEKIZUMAB reports
#2 most reported adverse reaction
PSORIASIS is the #2 most commonly reported adverse reaction for BIMEKIZUMAB, manufactured by UCB, Inc.. There are 1,713 FDA adverse event reports linking BIMEKIZUMAB to PSORIASIS. This represents approximately 6.8% of all 25,281 adverse event reports for this drug.
Patients taking BIMEKIZUMAB who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is moderately reported among BIMEKIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to psoriasis, the following adverse reactions have been reported for BIMEKIZUMAB:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 1,713 FDA reports for BIMEKIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 6.8% of all adverse event reports for BIMEKIZUMAB, making it one of the most commonly reported side effect.
If you experience psoriasis while taking BIMEKIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.